These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 29108162)

  • 1. Fetal Therapy for Down Syndrome: Report of Three Cases and a Review of the Literature.
    Baggot PJ; Baggot RM
    Issues Law Med; 2017; 32(1):31-41. PubMed ID: 29108162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular changes in fetal Down syndrome brain.
    Engidawork E; Lubec G
    J Neurochem; 2003 Mar; 84(5):895-904. PubMed ID: 12603815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Only a minority of sex chromosome abnormalities are detected by a national prenatal screening program for Down syndrome.
    Viuff MH; Stochholm K; Uldbjerg N; Nielsen BB; ; Gravholt CH
    Hum Reprod; 2015 Oct; 30(10):2419-26. PubMed ID: 26251461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant right subclavian artery in fetuses with Down syndrome: a systematic review and meta-analysis.
    Scala C; Leone Roberti Maggiore U; Candiani M; Venturini PL; Ferrero S; Greco T; Cavoretto P
    Ultrasound Obstet Gynecol; 2015 Sep; 46(3):266-76. PubMed ID: 25586729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fetal therapy for Down syndrome: an ethical exploration.
    de Wert G; Dondorp W; Bianchi DW
    Prenat Diagn; 2017 Mar; 37(3):222-228. PubMed ID: 28004394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Foetal therapy for Down syndrome: a pro-active ethical reflection].
    de Wert GM; Dondorp WJ
    Ned Tijdschr Geneeskd; 2016; 160():D307. PubMed ID: 27334087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial IFN-alpha/beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability.
    Maroun LE; Heffernan TN; Hallam DM
    J Interferon Cytokine Res; 2000 Feb; 20(2):197-203. PubMed ID: 10714556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Down syndrome in the fetus.
    Stephens TD; Shepard TH
    Teratology; 1980 Aug; 22(1):37-41. PubMed ID: 6449751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fetal hydrops and hepatosplenomegaly in the second half of pregnancy: a sign of myeloproliferative disorder in fetuses with trisomy 21.
    Smrcek JM; Baschat AA; Germer U; Gloeckner-Hofmann K; Gembruch U
    Ultrasound Obstet Gynecol; 2001 May; 17(5):403-9. PubMed ID: 11380964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down syndrome--genetic and nutritional aspects of accompanying disorders.
    Mazurek D; Wyka J
    Rocz Panstw Zakl Hig; 2015; 66(3):189-94. PubMed ID: 26400113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The relationship between weights of fetuses with autosomal trisomies and low maternal serum alpha-fetoprotein].
    Hsu JJ; Hsieh CC; Chiu TH; Soong YK
    Changgeng Yi Xue Za Zhi; 1992 Mar; 15(1):33-8. PubMed ID: 1374679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound detection and perinatal outcome of fetal trisomies 21, 18 and 13 in the absence of a routine fetal anomaly scan or biochemical screening.
    Moran CJ; Tay JB; Morrison JJ
    Ultrasound Obstet Gynecol; 2002 Nov; 20(5):482-5. PubMed ID: 12423486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fetal facial profile markers of Down syndrome in the second and third trimesters of pregnancy.
    Vos FI; de Jong-Pleij EA; Bakker M; Tromp E; Kagan KO; Bilardo CM
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):168-73. PubMed ID: 25366900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down syndrome passed from mother to child.
    Pachajoa H; Riascos AJ; Castro D; Isaza C; Quintero JC
    Biomedica; 2014; 34(3):326-9. PubMed ID: 25504119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.